Your gut bacteria may be shaping your cholesterol, study suggests

If your last blood panel came back with high cholesterol or triglycerides, you may have wondered whether your gut has anything to do with it. A new systematic review and meta-analysis published in Gastro Hep Advances, a journal of the American Gastroenterological Association, pooled data from 10 studies and more than 1,700 people to look for exactly that connection. The researchers did not find a single "cholesterol microbiome," but they did find a consistent pattern: three genera of gut bacteria known for producing helpful byproducts show up less often in people with hyperlipidemia (the medical term for chronically elevated cholesterol and/or triglycerides in the blood).

Key takeaways:

• Researchers pooled 10 studies (561 people with hyperlipidemia and 1,165 healthy controls) and found no overall difference in how diverse gut bacteria communities were between the two groups.
• Three specific genera, Faecalibacterium, Parabacteroides, and Roseburia, were consistently less abundant in people with hyperlipidemia across multiple studies.
• These bacteria are known for producing short-chain fatty acids (SCFAs) and bile-processing enzymes tied to lipid metabolism, but the study is observational, so it cannot show these bacteria cause high cholesterol.
• The authors call for longitudinal and interventional studies before any microbiome-based treatment for high cholesterol could be justified.

Faecalibacterium, Parabacteroides and Roseburia Run Low in Hyperlipidemia

The core finding is that three genera, Faecalibacterium, Parabacteroides, and Roseburia, were consistently reported as less abundant in people with hyperlipidemia compared to healthy controls, each showing up in four separate study comparisons within the review. What ties these three together is function: all three are known producers of short-chain fatty acids (SCFAs, small molecules made when gut bacteria ferment fiber) and some, like Parabacteroides, also produce bile salt hydrolase (BSH, an enzyme that helps process bile acids the body uses to digest fat and clear cholesterol). Notably, the researchers found no consistent difference in overall microbiome diversity (a measure of how many different bacterial species are present and how evenly distributed they are) between the two groups. In other words, it is not that people with high cholesterol have a "less diverse" gut in general, it is that a handful of specific, functionally important bacteria are running low.

Why High Cholesterol and Triglycerides Are Worth Watching

Hyperlipidemia, whether it shows up as high LDL (low-density lipoprotein, often called "bad cholesterol"), high triglycerides, or low HDL ("good cholesterol"), is one of the most common risk factors doctors screen for because of its direct link to cardiovascular disease. It is also a condition many people manage for years through diet, exercise, and medication without a full picture of why their numbers are stubborn. This review adds a plausible biological angle: several of the correlations held up when researchers looked at individual lipid markers rather than cholesterol as a whole. Triglyceride levels were negatively correlated with both Bifidobacterium and Faecalibacterium abundance, meaning less of these bacteria tracked with higher triglycerides. LDL was positively correlated with Agathobacter, and HDL was positively correlated with Bacteroides but negatively correlated with Bifidobacterium. For anyone already tracking their lipid panel, this is a reminder that gut health is one more thread researchers are actively pulling on, alongside diet, genetics, and metabolism, not a replacement for any of them.

A PRISMA-Guided Review of 10 Studies and 1,726 Participants

This was not a new experiment but a systematic review and meta-analysis, meaning the authors combed through existing research rather than enrolling new patients. They followed PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines and pre-registered their protocol with PROSPERO (an international registry for systematic reviews, registration number CRD42024549784). The team searched seven databases, including PubMed, Embase, and Web of Science, for case-control or cross-sectional studies comparing gut microbiota in adults with hyperlipidemia against healthy controls. Ten studies published between 2017 and 2024 met their criteria, together covering 561 people with hyperlipidemia and 1,165 controls, mostly from China, Japan, and South Korea, with additional studies from Chile and Poland. Because the review deliberately excluded people on cholesterol-lowering medication or dietary interventions, it captures what researchers call a "disease-associated" microbiome state, the bacterial picture before any treatment intervenes.

What This Means If You're Managing Your Own Cholesterol

For someone already working on their lipid numbers, the honest takeaway is: interesting, not actionable yet. This review does not test whether taking a probiotic, eating more fiber, or otherwise trying to boost Faecalibacterium or Roseburia would lower cholesterol. It only shows that these bacteria tend to be lower in people who already have high cholesterol, which could mean the bacteria influence lipid levels, that high lipid levels or the diet that drives them suppress the bacteria, or that some third factor, like fiber intake or metabolic health broadly, affects both independently. If you have hyperlipidemia, this is not a reason to abandon standard care, statins, diet changes, exercise, or whatever your doctor has recommended remain the established interventions. It is, however, a reasonable thing to mention if you are curious about the gut-metabolism connection at your next appointment, particularly if you are also managing gut symptoms alongside a lipid problem.

The Study Can't Establish Cause and Effect

The authors are direct about the limits here. Every included study was cross-sectional or case-control, meaning it captured a snapshot in time rather than tracking people over months or years, so it cannot show whether low levels of these bacteria came before high cholesterol or resulted from it. The review is also geographically lopsided, with most studies conducted in Asian populations, which limits how confidently the findings generalize to other groups. Most studies relied on 16S rRNA sequencing, a common but relatively coarse gut bacteria identification method that can identify genus-level bacteria but often can't distinguish between closely related species or strains, which may behave differently. The meta-regression analyses linking specific bacteria to specific lipid numbers, such as the association between Faecalibacterium and triglycerides, were also described by the authors as exploratory given the small number of studies available, and should be treated as hypothesis-generating rather than confirmed. One of the six authors, Jonathan Wei Jie Lee, disclosed being a co-founder and scientific advisory board member of AMILI, a microbiome company, a conflict of interest worth noting even though the review received no external funding.

Longitudinal and Multi-Omics Studies Are the Next Step

The authors are explicit that the field's next move needs to be longitudinal studies that track the same people's gut bacteria and lipid levels over time, alongside interventional trials that actually manipulate the microbiome, through diet, probiotics, or other means, to see if lipid levels move in response. Multi-omics studies, which combine microbiome data with metabolite and genetic data, were also flagged as necessary to clarify whether the SCFA and bile-acid pathways researchers suspect are actually doing the mechanistic work. No timeline was given, and this kind of interventional research typically takes years to design, run, and replicate.

Common Questions

Does this mean probiotics can lower my cholesterol? No. This review is observational, comparing existing gut bacteria levels between groups, and did not test any probiotic, supplement, or dietary intervention, so it cannot support that claim.

What do Faecalibacterium, Parabacteroides, and Roseburia actually do? All three are known for fermenting dietary fiber into short-chain fatty acids, metabolites linked to gut barrier health and reduced inflammation; Parabacteroides also produces an enzyme involved in processing bile acids that the body uses to digest fat and clear cholesterol.

Should I get a microbiome test if I have high cholesterol? This study does not establish that microbiome testing has any diagnostic or treatment value for hyperlipidemia yet, since the underlying research is still correlational and the authors themselves call for further study before drawing clinical conclusions.

Is this the first study to look at gut bacteria and cholesterol? No, smaller individual studies have explored this link before (see the related review on hyperlipidemia and gut microbiota metabolites); this is described by its authors as the first review to systematically pool and meta-analyze that existing evidence.

References

1. Chai Xian Hua, Hao Jeun Yap, David Bin-Chia Wu, Jonathan Wei Jie Lee, Chun Wie Chong, Doreen Su Yin Tan (2026). Gut Microbiota Associated With Hyperlipidemia: A Systematic Review and Meta-Analysis. Gastro Hep Advances. https://doi.org/10.1016/j.gastha.2026.101067
2. Xiaokang Jia, Wen Xu, Lei Zhang, Xiaoyan Li, Ruirui Wang, Shuisheng Wu (2021). Impact of Gut Microbiota and Microbiota-Related Metabolites on Hyperlipidemia. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2021.634780